blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3135668

EP3135668 - NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.10.2020
Database last updated on 29.06.2024
FormerThe patent has been granted
Status updated on  15.11.2019
FormerGrant of patent is intended
Status updated on  18.07.2019
FormerExamination is in progress
Status updated on  12.02.2019
FormerRequest for examination was made
Status updated on  27.01.2017
FormerThe international publication has been made
Status updated on  18.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi
Chuo-ku, Osaka-shi
Osaka 541-8505 / JP
[2019/50]
Former [2017/09]For all designated states
Mitsubishi Tanabe Pharma Corporation
2-10, Dosho-machi 3-chome Chuo-ku Osaka-shi
Osaka 541-8505 / JP
Inventor(s)01 / USHIROGOCHI, Hideki
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
02 / SASAKI, Wataru
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
03 / ONDA, Yuichi
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
04 / SAKAKIBARA, Ryo
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
05 / AKAHOSHI, Fumihiko
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
 [2017/12]
Former [2017/09]01 / USHIROGOCHI, Hideki
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
02 / SASAKI, Wataru
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
03 / ONDA, Yuichi
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
04 / SAKAKIBARA, Ryo
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
05 / AKAHOSHI, Fumihiko
c/o Mitsubishi Tanabe Pharma Corporation
3-2-10 Dosho-machi
Chuo-ku
Osaka-shi Osaka 541-8505 / JP
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2017/09]
Application number, filing date15782458.223.04.2015
[2017/09]
WO2015JP62440
Priority number, dateJP2014009075424.04.2014         Original published format: JP 2014090754
[2017/09]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015163427
Date:29.10.2015
Language:JA
[2015/43]
Type: A1 Application with search report 
No.:EP3135668
Date:01.03.2017
Language:EN
[2017/09]
Type: B1 Patent specification 
No.:EP3135668
Date:18.12.2019
Language:EN
[2019/51]
Search report(s)International search report - published on:JP29.10.2015
(Supplementary) European search report - dispatched on:EP19.02.2018
ClassificationIPC:C07D253/07, A61P13/12, A61P9/04, C07D451/02
[2019/31]
CPC:
C07D253/07 (EP,RU,US); C07D253/065 (RU); C07D253/06 (EP,KR,US);
A61K31/53 (EP,KR,RU,US); A61K31/5377 (EP,KR,RU,US); A61K31/541 (EP,KR,RU,US);
A61K31/553 (EP,KR,RU,US); A61P1/16 (RU); A61P13/12 (EP,RU,US);
A61P3/04 (RU); A61P9/00 (RU); A61P9/04 (EP,RU,US);
A61P9/08 (RU); A61P9/10 (RU); A61P9/12 (RU);
C07D401/04 (EP,RU,US); C07D401/12 (EP,RU,US); C07D401/14 (EP,KR,RU,US);
C07D403/04 (EP,RU,US); C07D403/12 (EP,US); C07D403/14 (EP,KR,RU,US);
C07D405/04 (EP,RU,US); C07D405/12 (EP,US); C07D405/14 (EP,KR,RU,US);
C07D409/04 (EP,US); C07D409/12 (EP,US); C07D409/14 (RU);
C07D413/04 (RU); C07D413/12 (EP,US); C07D413/14 (EP,RU,US);
C07D417/04 (EP,RU,US); C07D417/14 (RU); C07D451/02 (EP,US);
C07D453/02 (EP,US); C07D471/04 (EP,RU,US); C07D471/08 (EP,KR,RU,US);
C07D498/08 (EP,KR,RU,US); C07D498/10 (EP,KR,RU,US) (-)
Former IPC [2018/11]C07D253/07, A61K31/5377, A61K31/541, A61P9/00, A61P9/04, A61P9/08, A61P9/10, A61P9/12, A61P13/12, A61P25/00, A61P35/00, C07D451/02
Former IPC [2017/09]C07D253/06, A61K31/53, A61K31/5377, A61K31/541, A61P9/00, A61P9/04, A61P9/08, A61P9/10, A61P9/12, A61P13/12, A61P25/00, A61P35/00, C07D401/04, C07D401/12, C07D401/14, C07D403/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/09]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:NEUARTIGE DISUBSTITUIERTE 1,2,4-TRIAZIN-VERBINDUNG[2017/09]
English:NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND[2017/09]
French:NOUVEAU COMPOSÉ 1,2,4-TRIAZINE DISUBSTITUÉ[2017/09]
Entry into regional phase17.11.2016Translation filed 
17.11.2016National basic fee paid 
17.11.2016Search fee paid 
17.11.2016Designation fee(s) paid 
17.11.2016Examination fee paid 
Examination procedure17.11.2016Examination requested  [2017/09]
17.11.2016Date on which the examining division has become responsible
06.09.2018Amendment by applicant (claims and/or description)
15.02.2019Despatch of a communication from the examining division (Time limit: M04)
11.06.2019Reply to a communication from the examining division
19.07.2019Communication of intention to grant the patent
04.11.2019Fee for grant paid
04.11.2019Fee for publishing/printing paid
04.11.2019Receipt of the translation of the claim(s)
Opposition(s)21.09.2020No opposition filed within time limit [2020/48]
Fees paidRenewal fee
20.04.2017Renewal fee patent year 03
20.04.2018Renewal fee patent year 04
24.04.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL18.12.2019
CY18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MK18.12.2019
MT18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
IS18.04.2020
LU23.04.2020
[2022/32]
Former [2022/28]AL18.12.2019
CY18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MT18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
IS18.04.2020
LU23.04.2020
Former [2021/08]AL18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
IS18.04.2020
LU23.04.2020
Former [2020/52]AL18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
IS18.04.2020
Former [2020/51]AL18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
IS18.04.2020
Former [2020/40]AL18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
IS18.04.2020
Former [2020/37]AL18.12.2019
EE18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
Former [2020/35]AL18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RO18.12.2019
RS18.12.2019
BG18.03.2020
Former [2020/32]AL18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
BG18.03.2020
Former [2020/26]HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
BG18.03.2020
Former [2020/23]LT18.12.2019
LV18.12.2019
BG18.03.2020
Former [2020/22]LT18.12.2019
BG18.03.2020
Documents cited:Search[A]WO9113885  (BEECHAM GROUP PLC [GB]);
 [Y]WO2006081230  (SCHERING CORP [US], et al);
 [Y]US2007207985  (LI JUN [US], et al);
 [A]US2007292225  (SUZUKI MASAHARU [JP]);
 [Y]WO2011131593  (PF MEDICAMENT [FR], et al);
 [A]WO2013104597  (BAYER IP GMBH [DE]);
International search[A]WO2009156462  (NOVARTIS AG [CH], et al);
 [A]WO2010130796  (NOVARTIS AG [CH], et al);
 [A]WO2012012478  (MERCK SHARP & DOHME [US], et al);
 [A]WO2013037779  (HOFFMANN LA ROCHE [CH], et al);
 [A]WO2013079452  (HOFFMANN LA ROCHE [CH], et al);
by applicantWO0230891
 WO2010130796
 US2010292225
 WO2012012478
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.